Skip to main content

Contribute to a future without Parkinson’s disease

Do you want to contribute to a future without Parkinson’s disease? Apply Wilt u bijdragen aan een toekomst zonder parkinson? Then sign up for a non-binding conversation

What we’ve achieved so far

75

Trials

500

Participants

3

Locations

Our Parkinson’s trials

Filter

Parkinson's

LUMA

The goal of this study is to evaluate how safe and tolerable the new study drug RO7486967 is for the treatment of participants with early stage Parkinson’s disease (with slowness of movement, and resting tremor or rigidity). The study compares the effect of the study drug RO7486967 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience30-80 years

levelEarly stage Parkinson's disease

duration55 to 151 weeks

locationAmsterdam and Zwolle

Parkinson's

RO7486967

The goal of this study is to evaluate how safe and tolerable the new study drug RO7486967 is for the treatment of participants with early stage Parkinson’s disease (with slowness of movement, and resting tremor or rigidity). The study compares the effect of the study drug RO7486967 with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug is administered orally.

audience50-85 years

levelParkinson's disease

duration14 weeks

locationAmsterdam and Zwolle

Contact us

Do you have questions, or would you like to know more about one of our studies? Contact us by telephone or email. We are happy to help you.

Our partners

Our mission is to eliminate brain diseases, but we cannot do that alone. That is why we work together with leading partners.